These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Fc Receptor-mediated Effector Function Contributes to the Therapeutic Response of Anti-TNF Monoclonal Antibodies in a Mouse Model of Inflammatory Bowel Disease. McRae BL; Levin AD; Wildenberg ME; Koelink PJ; Bousquet P; Mikaelian I; Sterman AS; Bryant S; D'Haens G; Kamath R; Salfeld J; van den Brink GR J Crohns Colitis; 2016 Jan; 10(1):69-76. PubMed ID: 26429698 [TBL] [Abstract][Full Text] [Related]
6. Psoriasis induced by anti-tumour necrosis factor therapy in patients with inflammatory bowel disease. Salgueiro P; Lago P; Pedroto I J Crohns Colitis; 2013 Sep; 7(8):e325-6. PubMed ID: 23352103 [No Abstract] [Full Text] [Related]
7. Safe and effective: anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis. Kiely CJ; Subramaniam K; Platten J; Pavli P Intern Med J; 2016 May; 46(5):616-9. PubMed ID: 27170239 [TBL] [Abstract][Full Text] [Related]
8. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059 [TBL] [Abstract][Full Text] [Related]
9. Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease. Levin AD; Wildenberg ME; van den Brink GR J Crohns Colitis; 2016 Aug; 10(8):989-97. PubMed ID: 26896086 [TBL] [Abstract][Full Text] [Related]
10. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort. Bálint A; Rutka M; Végh Z; Kürti Z; Gecse KB; Banai J; Bene L; Gasztonyi B; Kristóf T; Lakatos L; Miheller P; Palatka K; Patai Á; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Bor R; Milassin Á; Fábián A; Nagy F; Kolar M; Bortlik M; Duricova D; Hruba V; Lukas M; Mitrova K; Malickova K; Lukas M; Lakatos PL; Molnár T; Farkas K Expert Opin Drug Saf; 2017 Aug; 16(8):885-890. PubMed ID: 28504555 [TBL] [Abstract][Full Text] [Related]
11. A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy. Picardo S; Seow CH Drugs; 2019 Jul; 79(10):1053-1063. PubMed ID: 31183768 [TBL] [Abstract][Full Text] [Related]
12. [Application of TNF-alpha blocker concentration assays in the treatment of inflammatory bowel diseases]. Sipponen T; Kolho KL Duodecim; 2013; 129(5):499-505. PubMed ID: 23520893 [TBL] [Abstract][Full Text] [Related]
13. Adherence to intravenous biological treatment in inflammatory bowel disease patients during the COVID-19 pandemic. Suárez Ferrer C; Pérez Robles T; Martín-Arranz MD Rev Esp Enferm Dig; 2021 Feb; 113(2):154. PubMed ID: 33371704 [TBL] [Abstract][Full Text] [Related]
14. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies. Ebert EC; Das KM; Mehta V; Rezac C Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498 [TBL] [Abstract][Full Text] [Related]
15. [Perspectives in inflammatory bowel diseases treatment]. Jalocha L; Wojtuń S; Dyrla P; Błaszak A; Wojtkowiak M; Zyśko B; Stelmaszuk T; Gil J Pol Merkur Lekarski; 2009 May; 26(155):556-8. PubMed ID: 19606725 [TBL] [Abstract][Full Text] [Related]
16. An update on biosimilar drugs for inflammatory bowel disease. Schreiber S Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529 [TBL] [Abstract][Full Text] [Related]
17. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978 [TBL] [Abstract][Full Text] [Related]
18. How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study. Bermejo F; Algaba A; Chaparro M; Taxonera C; Garrido E; García-Arata I; Guerra I; Gisbert JP; Olivares D; de-la-Poza G; López-Sanromán A Dig Liver Dis; 2013 Sep; 45(9):733-7. PubMed ID: 23587496 [TBL] [Abstract][Full Text] [Related]
19. Anti-TNF therapy in inflammatory bowel diseases: a huge review. Peyrin-Biroulet L Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259 [TBL] [Abstract][Full Text] [Related]
20. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Zelinkova Z; van der Ent C; Bruin KF; van Baalen O; Vermeulen HG; Smalbraak HJ; Ouwendijk RJ; Hoek AC; van der Werf SD; Kuipers EJ; van der Woude CJ; Clin Gastroenterol Hepatol; 2013 Mar; 11(3):318-21. PubMed ID: 23103819 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]